Technology Five days of remdesivir treatment: Coronavirus drug should cost 2,000 euros

08:50  30 june  2020
08:50  30 june  2020 Source:   tagesspiegel.de

Dr. Bonnie Henry says she's 'excited' about news of success with experimental drug for COVID-19

  Dr. Bonnie Henry says she's 'excited' about news of success with experimental drug for COVID-19 B.C.'s provincial health officer says she's cautiously optimistic about a new study on the experimental antiviral drug remdesivir's effects on COVID-19. American officials revealed this week that research conducted by the U.S. National Institutes of Health found remdesivir reduced recovery time by 31 per cent in COVID-19 patients — from 15 to 11 days on average.

The longer 10- day treatment course will cost governments ,290 per patient and $ 5 ,720 for a US “We wanted to make sure that nothing gets in the way of remdesivir getting to patients,” Gilead US Department of Health and Human Services (HSS) said it has secured more than 500, 000 treatment

Gilead Sciences said preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a five - day dosage of remdesivir The study tracked two groups of patients who were hospitalized with Covid-19. One group received a five - day treatment of remdesivir , while the other

Remdesivir is considered a beacon of hope. Now the US biotech company Gilead Sciences has published the price for a five-day treatment.

Eine fünftägige Behandlung mit Remdesivir soll pro Patient rund 2000 Euro kosten. © Photo: dpa / Fadel Dawood A five-day treatment with remdesivir should cost around 2000 euros per patient.

In the coronavirus pandemic, the US biotech company Gilead Sciences has set the price for the active ingredient remdesivir for the US market. A five-day treatment with remdesivir would cost $ 2340 per patient when ordered by the US government, Gilead chief Daniel O'Day wrote in an open letter on Monday.

The price for private health insurance is about a third higher. At this price, he estimated that everyone would have access to the drug, O'Day wrote. For countries in need, there will be generic versions of the drug at a lower price.

Does Remdesivir bring the virus to its knees?

 Does Remdesivir bring the virus to its knees? It is a glimmer of hope, nothing more and nothing less. A drug is now being used in the United States that could lead to faster recovery in COVID-19 patients. But that is not entirely certain. © AFP / U. Perrey Provided by Deutsche Welle The United States allows limited use of the active ingredient remdesivir in COVID-19 patients in hospitals. The exemption came in the light of the light of the coronavirus pandemic, Stephen Hahn chief of food and drug agency said in the White House.

A five - day treatment course using six vials of remdesivir is expected to cost a patient $ 2 ,340, which is well below the , 000 hospital savings stemming from an BofA's Take: BofA Securities has been estimating the total cost of remdesivir treatment at , 000 , with potential price controls factored in

The antiviral remdesivir was shown to shorten recovery times for coronavirus patients in clinical trials, though it Gilead Sciences, the maker of the first covid-19 treatment found to have worked in clinical trials “Gilead did not make remdesivir alone. Public funding was indispensable at each stage, and

Only a few days ago, the European Medicines Agency (EMA) recommended that the product with the trade name Veklury should also be approved in Europe. An international study with over 1000 participants showed at the end of April that remdesivir in Covid 19 patients could reduce the time to recovery by an average of four days - from 15 to 11 days.

The mortality rate decreased slightly in the study, but this was not statistically significant. The USA had already granted a special permit for the limited use of the active ingredient in hospitals at the beginning of May.

[If you want to have all the latest developments on the coronavirus crisis live on your mobile phone, we recommend our completely renewed app, which you can download here for Apple and Android devices .]

So far, the remedy has also been available in Germany accessible within a drug hardship program and is tested in clinical studies. Remdesivir was originally developed to treat Ebola, but was not effective enough.

It has not yet been approved as a medication in any country in the world. So far there is no vaccination against the novel corona virus and no reliable approved drug therapy . (dpa)

More on MSN

Covid-19: the European Medicines Agency recommends authorizing remdesivir .
© Ulrich Perrey, pool / AFP (archives) A sample of remdesivir photographed during a press conference on 8 April 2020 in Hamburg. The European Medicines Agency (EMA) recommended Thursday the authorization of a "conditional marketing" of the antiviral remdesivir within the European Union for patients with the new coronavirus. The antiviral remdesivir is on track to be marketed in Europe to treat patients with Covid-19.

—   Share news in the SOC. Networks
usr: 0
This is interesting!